Total
0
Shares
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating
CEO & Managing Director, Dr Tony Keating
Source: ResApp Health
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • ResApp Health (RAP) locks in a three-year licensing agreement with Janssen Pharmaceutica NV for use of its ResAppDx technology in a trial
  • The study will see ResAppDx used by Janssen to assess the respiratory symptoms of a group of patients with a range of respiratory diseases
  • Janssen will pay development and maintenance costs, in addition to a fee for each ResAppDx test used
  • The trial is set to be conducted across the US, Europe, South America, and Asia Pacific later this year
  • ResApp shares last traded at 5.3 cents on November 17

ResApp Health (RAP) has locked in a three-year licensing agreement for use of its ResAppDx technology in a respiratory syncytial virus clinical trial.

ResAppDx is a diagnostic test that uses machine-learning technology to analyse cough sounds to diagnose respiratory disease using a smartphone’s inbuilt microphone.

The digital health company secured the non-exclusive agreement with Janssen Pharmaceutica NV, one of the pharmaceutical companies of Johnson & Johnson, for use of its technology to study respiratory syncytial virus (RSV).

The trial will see ResAppDx used by Janssen to assess the respiratory symptoms of a group of patients with a range of respiratory diseases, including RSV. This marks the first time ResAppDx has ever been used by a third party to monitor patients in a clinical trial setting.

RSV is a virus that causes respiratory infections, like inflammation of the small breathing tubes of the lung and pneumonia. Severe cases of the illness can spread to the lower respiratory tract, causing chronic obstructive pulmonary disease or asthma. The company noted almost 160,000 people die each year as a result of RSV.

Janssen will pay development and maintenance costs, in addition to a fee for each ResAppDx test used.

“With this agreement, we are demonstrating that leading global pharmaceutical companies see the value of ResAppDx in a clinical trial setting,” ResApp Health CEO and Managing Director Tony Keating said.

“While not expected to have a material impact on our operating results at this stage, this contract represents the beginning of our commercial relationship with Janssen and will further build the body of high quality, clinical evidence regarding the use of ResAppDx.”

The trial is set to be conducted across the US, Europe, South America and the Asia Pacific later this year.

ResApp shares last traded at 5.3 cents on November 17.

RAP by the numbers
More From The Market Herald
icetana Limited, ICE - CEO, Matthew Macfarlane

" icetana Limited (ASX:ICE) signs Memorandum of Understanding with Threat Protect (ASX:TPS)

icetana Limited (ICE) has signed a memorandum of understanding with Threat Protect Australia (TPS).
Pan Asia Metals (ASX:PAM) - Managing Director, Paul Lock

" Pan Asia Metals (ASX:PAM) announces latest drilling results from Reung Kiet lithium project, Thailand

Pan Asia Metals (PAM) has released lithium drill results for four holes from its Reung Kiet project in southern Thailand.
APM (ASX:APM) - CEO, Michael Anghie

" APM Human Services (ASX:APM) expands, acquiring Lifecare

APM Human Services International (APM) has acquired physiotherapy and home care group Lifecare for $68 million.

" Celamin (ASX:CNL) secures commitments to raise $3.2m

Celamin Holdings (CNL) has secured binding commitments to raise $3.2 million at 7.5 cents per share. The company will issue up to 42.6...